


PRODUCT INFORMATION



LDN-211904

Item No. 20453

CAS Registry No.: 1198408-78-4
Formal Name: N-(2-chlorophenyl)-6-(4-piperidiny)-imidazo[1,2-a]pyridine-3-carboxamide, monoethanedioate
MF: C₁₉H₁₉ClN₄O • C₂H₂O₄
FW: 444.9
Purity: ≥95%
UV/Vis.: λ_{max}: 211, 250, 303 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LDN-211904 is supplied as a crystalline solid. A stock solution may be made by dissolving the LDN-211904 in the solvent of choice, which should be purged with an inert gas. LDN-211904 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of LDN-211904 in these solvents is approximately 20 and 0.5 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of LDN-211904 can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of LDN-211904 in PBS, pH 7.2, is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

LDN-211904 is an inhibitor of erythropoietin-producing hepatocellular carcinoma (Eph) receptors. In particular, it inhibits EphB3 (IC₅₀ = 79 nM), a receptor tyrosine kinase (RTK) subtype expressed during embryonic development and following central nervous system damage and some cancer cell growth.¹ At 5 μM, this compound was profiled for inhibitory activity against a panel of 288 kinases and found to inhibit most of the EphA and EphB receptor kinase subtypes except for EphA6 and EphA7, and is non-inhibitory towards the non-RTKs screened except for p38α, p38β, and Qik.¹

Reference

1. Qiao, L., Choi, S., Case, A., *et al.* Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors. *Bioor. Med. Chem. Lett.* **19(21)**, 6122-6126 (2009).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/06/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM